Portfolio news Archives - Page 12 of 13

Polyneuron Pharmaceuticals granted the FDA orphan drug designation

The orphan drug designation can only be granted for treatments on rare diseases to advance the developments of safe and effective therapies and the FDA…

clement19.08.2020

female laboratory worker looking into microscope

All Portfolio news

PharmaBiome secures CHF 1.75 million

PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome…

clement19.08.2020

Female scientist working in a laboratory

All Portfolio news

T3 Pharma raises over 25 million Swiss francs

T3 Pharmaceuticals (T3 Pharma) has successfully closed a third financing round, raising over 25 million Swiss francs. According to a press release, the financing was co-led…

Emma Bulmer27.07.2020

All Portfolio news

New partner announcement: BB Pureos Bioventures

We are proud to announce that BB Pureos Bioventures has become a partner in BaseLaunch Phase II as the first venture capital fund. Anja Harmeier,…

clement08.06.2020

All Portfolio news

Polyneuron recieves approval to begin clinical study

Congratulations to one of BaseLaunch’s portfolio companies, Polyneuron on their latest milestone: First clinical trial application approval. Wishing you great success with the studies later…

clement11.05.2020

All Portfolio news

Anaveon raises CHF 35 million

Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the…

clement05.03.2020

All Portfolio news

Polyneuron raises CHF 22.5 million in Series A financing

Polyneuron Pharmaceuticals, one of our portfolio companies has successfully raised 22.5 million francs in a round of financing. The Basel-based company will use the proceeds…

clement04.03.2020

All Portfolio news

Alentis raises 12.5 million Swiss francs

The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by…

clement03.03.2020

All Portfolio news

T3 Pharma raises over $12 million

T3 Pharma, a spin-off of the University of Basel and one of our portfolio, has raised over $12 million from Boehringer Ingelheim Venture Fund and…

clement02.03.2020

All Portfolio news

Versameb raises 6.4 million Swiss francs

Basel-based biopharmaceutical Versameb has raised 6.4 million Swiss francs in a Seed C financing round and will put the funds towards expanding its technology platform.…

clement01.03.2020

Portfolio news

Polyneuron Pharmaceuticals granted the FDA orphan drug designation

PharmaBiome secures CHF 1.75 million

T3 Pharma raises over 25 million Swiss francs

New partner announcement: BB Pureos Bioventures

Polyneuron recieves approval to begin clinical study

Anaveon raises CHF 35 million

Polyneuron raises CHF 22.5 million in Series A financing

Alentis raises 12.5 million Swiss francs

T3 Pharma raises over $12 million

Versameb raises 6.4 million Swiss francs

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us